Interestingly, CXCL2 levels were markedly upregulated in STAD patients compared with healthy volunteers in subgroup analysis based on age, gender, tumor grade, TP53 mutation status, individual cancer stage, and nodal metastasis status (Fig. 2A–F). This evidence concerns the gene CXCL2 and gastric adenocarcinoma.